Arianna  Gentilini

Arianna Gentilini

PhD student

LSE Health

Connect with me

English, French, Italian, Spanish
Key Expertise
Health Economics, Pharmaceutical Policy, Rare Diseases

About me

Arianna Gentilini joined the department in 2020. Her PhD focuses on the role of patient organisations and other stakeholders in innovation of and access to medicines for rare diseases in high-income countries. She is particularly interested in understanding the role patient advocacy plays in R&D and how patients’ voices are integrated in the regulatory and reimbursement processes. In her research, Arianna employs both quantitative and qualitative methods, including econometric analysis, document analysis, and interviews.

Her research has been published in high-impact journals, such as the BMJ, BMJ Open and Social Science & Medicine, and has received media coverage in The Observer.

Alongside her research, Arianna works as a Senior Researcher at the Medical Technology Research Group (MTRG), LSE Health as well as consulting for the World Bank. She is also a Visiting Fellow at Imperial College Business School. Prior joining LSE, she worked as consultant in HEOR consultancies focusing on health economics and market access. She holds an MSc in International Health Policy (Health Economics) with Distinction from LSE and a BSc in International Economics with Honours from the University of Padova.


Dissertation title:

The role of patient organisations in innovation and access: Evidence from rare diseases 


Dissertation supervisor(s):

Dr Panos Kanavos, Professor Alistair McGuire, Professor Andrew Street 



Please view from here.

Personal website



  • Kanavos P, Visentin E, Gentilini A (2023). Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries. Social Science & Medicine.
  • Gentilini A, Parvanova I (2023). Industry Funding of Patient Organisations in the United Kingdom: A Retrospective Study of Commercial Determinants, Funding Concentration and Disease Prevalence. BMJ Open;